Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM0709
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
SIM0709 is a humanized, long-acting bispecific monoclonal antibody designed to simultaneously target tumor necrosis factor ligand superfamily member 15 (TL1A) and the p19 subunit of interleukin-23 (IL-23p19). Developed by Simcere Pharmaceutical Group using its proprietary multi-specific antibody platform, SIM0709 aims to block two key inflammatory pathways involved in the pathogenesis of inflammatory bowel disease (IBD). Preclinical studies have demonstrated superior synergistic efficacy compared to the combination of individual monotherapies, suggesting a potent therapeutic potential for chronic inflammatory conditions. In January 2026, Boehringer Ingelheim entered into a significant licensing agreement with Simcere, acquiring global development and commercialization rights for SIM0709 outside of Greater China.
- Other names
- TL1A/LZg/16
02
Targets
IL23A (Interleukin-23 p19 Subunit)TL1A (TNF-like cytokine 1A)
Beyond the preview
Go deeper on SIM0709.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM0709.